-
1
-
-
0003474764
-
-
3rd edn. McLean, VA: Degnon Associates, Inc.
-
Drossman DA, Corazziari E, Delvaux M, et al. Rome III: The Functional Gastrointestinal Disorders. 3rd edn. McLean, VA: Degnon Associates, Inc., 2006.
-
(2006)
Rome III: The Functional Gastrointestinal Disorders
-
-
Drossman, D.A.1
Corazziari, E.2
Delvaux, M.3
-
2
-
-
0032615306
-
Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: Results from the Domestic/International Gastroenterology Surveillance Study (DIGEST)
-
Stanghellini V. Three-Month Prevalence Rates of Gastrointestinal Symptoms and the Influence of Demographic Factors: Results from the Domestic/ International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999;231:20-8. (Pubitemid 29510674)
-
(1999)
Scandinavian Journal of Gastroenterology, Supplement
, vol.33
, Issue.231
, pp. 20-28
-
-
Stanghellini, V.1
-
3
-
-
0035035987
-
Prevalence of functional dyspepsia and its relationship with Helicobacter pylori infection in a Japanese population
-
DOI 10.1046/j.1440-1746.2001.02454.x
-
Kawamura A, Adachi K, Takashima T, et al. Prevalence of functional dyspepsia and its relationship with Helicobacter pylori infection in a Japanese population. J Gastroenterol Hepatol 2001;16:384-8. (Pubitemid 32397649)
-
(2001)
Journal of Gastroenterology and Hepatology
, vol.16
, Issue.4
, pp. 384-388
-
-
Kawamura, A.1
Adachi, K.2
Takashima, T.3
Murao, M.4
Katsube, T.5
Yuki, M.6
Watanabe, M.7
Kinoshita, Y.8
-
4
-
-
77949263569
-
Prevalence of functional dyspepsia in an outpatient clinic with primary care physicians in Japan
-
Okumura T, Tanno S, Ohhira M, et al. Prevalence of functional dyspepsia in an outpatient clinic with primary care physicians in Japan. J Gastroenterol 2010;45:187-94.
-
(2010)
J Gastroenterol
, vol.45
, pp. 187-194
-
-
Okumura, T.1
Tanno, S.2
Ohhira, M.3
-
5
-
-
57449096143
-
The spectra of functional gastrointestinal disorders (FGID) in a Japanese hospital outpatient department according to the ROME II Integrative Questionnaire
-
Nakajima S. The spectra of functional gastrointestinal disorders (FGID) in a Japanese hospital outpatient department according to the ROME II Integrative Questionnaire. J Gastroenterol Hepatol 2008;23(Suppl 2):S186-92.
-
(2008)
J Gastroenterol Hepatol
, vol.23
, Issue.SUPPL. 2
-
-
Nakajima, S.1
-
6
-
-
77952743651
-
Functional dyspepsia impacts absenteeism and direct and indirect costs
-
Brook RA, Kleinman NL, Choung RS, et al. Functional dyspepsia impacts absenteeism and direct and indirect costs. Clin Gastroenterol Hepatol 2010;8:498-503.
-
(2010)
Clin Gastroenterol Hepatol
, vol.8
, pp. 498-503
-
-
Brook, R.A.1
Kleinman, N.L.2
Choung, R.S.3
-
7
-
-
27744445389
-
American gastroenterological association technical review on the evaluation of dyspepsia
-
DOI 10.1053/j.gastro.2005.09.020, PII S0016508505018184
-
Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology 2005;129:1756-80. (Pubitemid 41597412)
-
(2005)
Gastroenterology
, vol.129
, Issue.5
, pp. 1756-1780
-
-
Talley, N.J.1
Vakil, N.B.2
Moayyedi, P.3
-
9
-
-
79953668479
-
Acotiamide (Z-338, YM443), a new drug for the treatment of functional dyspepsia
-
Tack J, Janssen P. Acotiamide (Z-338, YM443), a new drug for the treatment of functional dyspepsia. Expert Opin Investig Drugs 2011;20:701-12.
-
(2011)
Expert Opin Investig Drugs
, vol.20
, pp. 701-712
-
-
Tack, J.1
Janssen, P.2
-
10
-
-
0033946232
-
Z-338 facilitates acetylcholine release from enteric neurons due to blockade of muscarinic autoreceptors in guinea pig stomach
-
Ogishima M, Kaibara M, Ueki S, et al. Z-338 facilitates acetylcholine release from enteric neurons due to blockade of muscarinic autoreceptors in guinea pig stomach. J Pharmacol Exp Ther 2000;294:33-7. (Pubitemid 30434667)
-
(2000)
Journal of Pharmacology and Experimental Therapeutics
, vol.294
, Issue.1
, pp. 33-37
-
-
Ogishima, M.1
Kaibara, M.2
Ueki, S.3
Kurimoto, T.4
Taniyama, K.5
-
11
-
-
0033862522
-
Z-338 a newly synthesized carboxyamide derivative, stimulates gastric motility through enhancing the excitatory neurotransmission
-
Nakajima T, Nawata H, Ito Y. Z-338 a newly synthesized carboxyamide derivative, stimulates gastric motility through enhancing the excitatory neurotransmission. J Smooth Muscle Res 2000;36:69-81.
-
(2000)
J Smooth Muscle Res
, vol.36
, pp. 69-81
-
-
Nakajima, T.1
Nawata, H.2
Ito, Y.3
-
12
-
-
49749087225
-
Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats
-
Seto K, Sasaki T, Katsunuma K, et al. Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. Neurogastroenterol Motil 2008;20:1051-9.
-
(2008)
Neurogastroenterol Motil
, vol.20
, pp. 1051-1059
-
-
Seto, K.1
Sasaki, T.2
Katsunuma, K.3
-
13
-
-
77950503626
-
Clinical trial: Dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia 100mg t.i.d. is an optimal dosage
-
Matsueda K, Hongo M, Tack J, et al. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia 100mg t.i.d. is an optimal dosage. Neurogastroenterol Motil 2010;22:618-27.
-
(2010)
Neurogastroenterol Motil
, vol.22
, pp. 618-627
-
-
Matsueda, K.1
Hongo, M.2
Tack, J.3
-
14
-
-
60649100914
-
A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia
-
Tack J, Masclee A, Heading R, et al. A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil 2009;21:272-80.
-
(2009)
Neurogastroenterol Motil
, vol.21
, pp. 272-280
-
-
Tack, J.1
Masclee, A.2
Heading, R.3
-
15
-
-
46749088568
-
A novel acetylcholine esterase inhibitor acotiamide hydrochloride (YM443) in functional dyspepsia: Efficacy in a randomized, double-blind, placebo-controlled dose ranging trial
-
Talley N, Tack J, Kowalski D, et al. A novel acetylcholine esterase inhibitor acotiamide hydrochloride (YM443) in functional dyspepsia: efficacy in a randomized, double-blind, placebo-controlled dose ranging trial. Gastroenterology 2008;134:A157.
-
(2008)
Gastroenterology
, vol.134
-
-
Talley, N.1
Tack, J.2
Kowalski, D.3
-
16
-
-
77951962316
-
Influence of PPI run-in, pH monitoring and nutrient tolerance on efficacy outcomes of acotiamide hydrochloride (YM443), a novel acetylcholine esterase inhibitor, in functional dyspepsia
-
Tack J, Talley N, Kowalski D, et al. Influence of PPI run-in, pH monitoring and nutrient tolerance on efficacy outcomes of acotiamide hydrochloride (YM443), a novel acetylcholine esterase inhibitor, in functional dyspepsia. Gastroenterology 2008;134:16.
-
(2008)
Gastroenterology
, vol.134
, pp. 16
-
-
Tack, J.1
Talley, N.2
Kowalski, D.3
-
17
-
-
79951665389
-
Endpoints used in functional dyspepsia drug therapy trials
-
Ang D, Talley NJ, Simren M, et al. Endpoints used in functional dyspepsia drug therapy trials. Aliment Pharmacol Ther 2011;33:634-49.
-
(2011)
Aliment Pharmacol Ther
, vol.33
, pp. 634-649
-
-
Ang, D.1
Talley, N.J.2
Simren, M.3
-
18
-
-
0023232668
-
A comparison of likert and visual analogue scales for measuring change in function
-
DOI 10.1016/0021-9681(87)90080-4
-
Guyatt GH, Townsend M, Berman LB, et al. A comparison of Likert and Visual Analogue Scales for measuring change in function. J Chronic Dis 1987;40:1129-33. (Pubitemid 17158144)
-
(1987)
Journal of Chronic Diseases
, vol.40
, Issue.12
, pp. 1129-1133
-
-
Guyatt, G.H.1
Townsend, M.2
Berman, L.B.3
Keller, J.L.4
-
19
-
-
0035074507
-
Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: A meta-analysis
-
DOI 10.1016/S0002-9270(00)02314-5, PII S0002927000023145
-
Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, et al. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001;96:689-96. (Pubitemid 32240716)
-
(2001)
American Journal of Gastroenterology
, vol.96
, Issue.3
, pp. 689-696
-
-
Veldhuyzen, V.Z.S.J.O.1
Jones, M.J.2
Verlinden, M.3
Talley, N.J.4
-
20
-
-
0029873337
-
Drug treatment of functional dyspepsia: A systematic analysis of trial methodology with recommendations for design of future trials
-
Veldhuyzen van Zanten SJ, Cleary C, Talley NJ, et al. Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol 1996;91:660-73. (Pubitemid 26117940)
-
(1996)
American Journal of Gastroenterology
, vol.91
, Issue.4
, pp. 660-673
-
-
Veldhuyzen, V.Z.S.J.O.1
Cleary, C.2
Talley, N.J.3
Peterson, T.C.4
Nyren, O.5
Bradley, L.A.6
Verlinden, M.7
Tytgat, G.N.J.8
-
21
-
-
0037181736
-
Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: The Canadian adult dyspepsia empiric treatment - Helicobacter pylori positive (CADET-Hp) randomised controlled trial
-
Chiba N, Van Zanten SJ, Sinclair P, et al. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: The Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-HP) randomised controlled trial. BMJ 2002;324:1012-16. (Pubitemid 34457514)
-
(2002)
British Medical Journal
, vol.324
, Issue.7344
, pp. 1012-1016
-
-
Chiba, N.1
Veldhuyzen, V.Z.S.J.O.2
Sinclair, P.3
Ferguson, R.A.4
Escobedo, S.5
Grace, E.6
-
22
-
-
19544378003
-
2-RA-start' management strategies in primary care - The CADET-HR Study
-
DOI 10.1111/j.1365-2036.2005.02466.x
-
Armstrong D, Veldhuyzen van Zanten SJ, Barkun AN, et al; the CADET-HR Study Group. Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-Start' and 'H2-RA-Start' management strategies in primary care. The CADET-HR Study. Aliment Pharmacol Ther 2005;21:1189-202. (Pubitemid 40733484)
-
(2005)
Alimentary Pharmacology and Therapeutics
, vol.21
, Issue.10
, pp. 1189-1202
-
-
Armstrong, D.1
Veldhuyzen, V.Z.S.J.O.2
Barkun, A.N.3
Chiba, N.4
Thomson, A.B.R.5
Smyth, S.6
Sinclair, P.7
Chakraborty, B.8
White, R.J.9
-
23
-
-
33748369872
-
Esomeprazole 40 mg once a day in patients with functional dyspepsia: The randomized, placebo-controlled "ENTER" trial
-
DOI 10.1111/j.1572-0241.2006.00751.x
-
Van Zanten SJ, Armstrong D, Chiba N, et al. Esomeprazole 40 mg once a day in patients with functional dyspepsia: The Randomized, Placebo-Controlled "ENTER" Trial. Am J Gastroenterol 2006;101:2096-106. (Pubitemid 44337636)
-
(2006)
American Journal of Gastroenterology
, vol.101
, Issue.9
, pp. 2096-2106
-
-
Van Zanten, S.V.1
Armstrong, D.2
Chiba, N.3
Flook, N.4
White, R.J.5
Chakraborty, B.6
Gasco, A.7
-
24
-
-
49349102447
-
Tegaserod treatment for functional dyspepsia dysmotility symptoms: Results of two randomized, controlled trials
-
Vakil N, Laine L, Talley NJ, et al. Tegaserod treatment for functional dyspepsia dysmotility symptoms: results of two randomized, controlled trials. Am J Gastroenterol 2008;103:1906-19.
-
(2008)
Am J Gastroenterol
, vol.103
, pp. 1906-1919
-
-
Vakil, N.1
Laine, L.2
Talley, N.J.3
-
25
-
-
0033199083
-
Validity of a new quality of life scale for functional dyspepsia: A United States multicenter trial of the Nepean Dyspepsia Index
-
DOI 10.1111/j.1572-0241.1999.01363.x, PII S0002927099004190
-
Talley NJ, Verlinden M, Jones M. Validity of a new quality of life scale for functional dyspepsia: a United states multicenter trial of the Nepean Dyspepsia Index. Am J Gastroenterol 1999;94:2390-7. (Pubitemid 29420662)
-
(1999)
American Journal of Gastroenterology
, vol.94
, Issue.9
, pp. 2390-2397
-
-
Talley, N.J.1
Verlinden, M.2
Jones, M.3
-
26
-
-
0035126078
-
Quality of life in functional dyspepsia: Responsiveness of the Nepean Dyspepsia Index and development of a new 10-item short form
-
DOI 10.1046/j.1365-2036.2001.00900.x
-
Talley NJ, Verlinden M, Jones M. Quality of life in functional dyspepsia: responsiveness of the Nepean Dyspepsia Index and development of a new-10 item short form. Aliment Pharmacol Ther 2001;15:207-16. (Pubitemid 32142498)
-
(2001)
Alimentary Pharmacology and Therapeutics
, vol.15
, Issue.2
, pp. 207-216
-
-
Talley, N.J.1
Verlinden, M.2
Jones, M.3
-
27
-
-
49149121213
-
The use of patient-reported outcome measures in the evaluation of medical products for regulatory approval
-
Burke LB, Kennedy DL, Miskala PH, et al. The use of patient-reported outcome measures in the evaluation of medical products for regulatory approval. Clin Pharmacol Ther 2008;84:281-3.
-
(2008)
Clin Pharmacol Ther
, vol.84
, pp. 281-283
-
-
Burke, L.B.1
Kennedy, D.L.2
Miskala, P.H.3
-
28
-
-
77950502427
-
Evolution of clinical trials for irritable bowel syndrome: Issues in end points and study design
-
Trentacosti AM, He R, Burke LB, et al. Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design. Am J Gastroenterol 2010;105:731-5.
-
(2010)
Am J Gastroenterol
, vol.105
, pp. 731-735
-
-
Trentacosti, A.M.1
He, R.2
Burke, L.B.3
-
29
-
-
22744457475
-
A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: The CADET-HN study
-
DOI 10.1111/j.1572-0241.2005.40280.x
-
Veldhuyzen van Zanten SJ, Chiba N, Armstrong D, et al. A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN study. Am J Gastroenterol 2005;100:1477-88. (Pubitemid 41032350)
-
(2005)
American Journal of Gastroenterology
, vol.100
, Issue.7
, pp. 1477-1488
-
-
Veldhuyzen, V.Z.S.J.O.1
Chiba, N.2
Armstrong, D.3
Barkun, A.4
Thomson, A.5
Smyth, S.6
Escobedo, S.7
Lee, J.8
Sinclair, P.9
-
30
-
-
0032564656
-
Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia
-
Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group
-
Blum AL, Talley NJ, O'Morain C, et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med 1998;339:1875-81.
-
(1998)
N Engl J Med
, vol.339
, pp. 1875-1881
-
-
Blum, A.L.1
Talley, N.J.2
O'Morain, C.3
-
31
-
-
0024852022
-
Measurement of health status. Ascertaining the minimal clinically important difference
-
DOI 10.1016/0197-2456(89)90005-6
-
Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-15. (Pubitemid 20025670)
-
(1989)
Controlled Clinical Trials
, vol.10
, Issue.4
, pp. 407-415
-
-
Jaeschke, R.1
Singer, J.2
Guyatt, G.H.3
-
32
-
-
0036893791
-
Functional heartburn: The stimulus, the pain, and the brain
-
DOI 10.1136/gut.51.6.885
-
Fass R, Tougas G. Functional heartburn: the stimulus, the pain and the brain. Gut 2002;51:885-92. (Pubitemid 35408615)
-
(2002)
Gut
, vol.51
, Issue.6
, pp. 885-892
-
-
Fass, R.1
Tougas, G.2
-
33
-
-
27744571011
-
Guideline for the management of dyspepsia
-
Practice Parameters Committee of the American College of Gastroenterology
-
Talley NJ, Vakil N; Practice Parameters Committee of the American College of Gastroenterology. Guideline for the management of dyspepsia. Am J Gastroenterol 2005;100:2324-37.
-
(2005)
Am J Gastroenterol
, vol.100
, pp. 2324-2337
-
-
Talley, N.J.1
Vakil, N.2
-
34
-
-
0036234667
-
Dose finding study of mosapride in functional dyspepsia: A placebo-controlled, randomized study
-
DOI 10.1046/j.1365-2036.2002.01236.x
-
Hallerback BI, Bommelaer G, Bredberg E, et al. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther 2002;16:959-67. (Pubitemid 34461766)
-
(2002)
Alimentary Pharmacology and Therapeutics
, vol.16
, Issue.5
, pp. 959-967
-
-
Hallerback, B.I.1
Bommelaer, G.2
Bredberg, E.3
Campbell, M.4
Hellblom, M.5
Lauritsen, K.6
Wienbeck, M.7
Holmgren, L.-L.8
-
35
-
-
33344478892
-
A placebo-controlled trial of itopride in functional dyspepsia
-
DOI 10.1056/NEJMoa052639
-
Holtmann G, Talley NJ, Liebregts T, et al. A placebo-controlled trial of Itopride in functional dyspepsia. N Engl J Med 2006;354:832-40. (Pubitemid 43290921)
-
(2006)
New England Journal of Medicine
, vol.354
, Issue.8
, pp. 832-840
-
-
Holtmann, G.1
Talley, N.J.2
Liebregts, T.3
Adam, B.4
Parow, C.5
-
36
-
-
44149124107
-
Itopride in functional dyspepsia: Results of two phase III multicentre, randomised, double-blind, placebo-controlled trials
-
DOI 10.1136/gut.2007.132449
-
Talley NJ, Tack J, Ptak T, et al. Itopride in functional dyspepsia: results of two Phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut 2008;57:740-6. (Pubitemid 351716964)
-
(2008)
Gut
, vol.57
, Issue.6
, pp. 740-746
-
-
Talley, N.J.1
Tack, J.2
Ptak, T.3
Gupta, R.4
Giguere, M.5
-
37
-
-
0013418378
-
A Phase II placebo controlled randomized trial with tegaserod in functional dyspepsia patients with normal gastoric emptying
-
Tack J, Delia T, Ligozio G, et al. A Phase II placebo controlled randomized trial with tegaserod in functional dyspepsia patients with normal gastoric emptying. Gastroenterology 2002;122:154.
-
(2002)
Gastroenterology
, vol.122
, pp. 154
-
-
Tack, J.1
Delia, T.2
Ligozio, G.3
-
39
-
-
0141539377
-
Consensus report: Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome
-
DOI 10.1046/j.1365-2036.2003.01709.x
-
Corazziari E, Bytzer P, Delvaux M, et al. Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2003;18:569-80. (Pubitemid 37186606)
-
(2003)
Alimentary Pharmacology and Therapeutics
, vol.18
, Issue.6
, pp. 569-580
-
-
Corazziari, E.1
Bytzer, P.2
Delvaux, M.3
Holtmann, G.4
Malagelada, J.R.5
Morris, J.6
Muller-Lissner, S.7
Spiller, R.C.8
Tack, J.9
Whorwell, P.J.10
-
40
-
-
66949172842
-
Minimum clinically important difference for the Nepean Dyspepsia Index, a validated quality of life scale for functional dyspepsia
-
Jones M, Talley NJ. Minimum clinically important difference for the Nepean Dyspepsia Index, a validated quality of life scale for functional dyspepsia. Am J Gastroenterol 2009;104:1483-8.
-
(2009)
Am J Gastroenterol
, vol.104
, pp. 1483-1488
-
-
Jones, M.1
Talley, N.J.2
-
41
-
-
0033258353
-
Cardiac adverse effects of gastrointestinal prokinetics
-
DOI 10.1046/j.1365-2036.1999.00655.x
-
Tonini T, De Ponti F, Di Nucci A, et al. Cardiac adverse effects of gastrointestinal prokinetics. Aliment Pharmacol Ther 1999;13:1585-91. (Pubitemid 30009075)
-
(1999)
Alimentary Pharmacology and Therapeutics
, vol.13
, Issue.12
, pp. 1585-1591
-
-
Tonini, M.1
De Ponti, F.2
Di, N.A.3
Crema, F.4
-
42
-
-
45849137830
-
Tegaserod withdrawal from the world market. A treatment for constipation with cardiovascluar adverse effect
-
Anon.
-
Anon. Tegaserod withdrawal from the world market. A treatment for constipation with cardiovascluar adverse effect. Prescrire Int 2008;17:112-13.
-
(2008)
Prescrire Int
, vol.17
, pp. 112-113
-
-
-
44
-
-
79953666705
-
Z-338 improves meal-induced symptoms in Functional Dyspepsia: A double-blind, randomized, placebo controlled crossover study
-
Adam B, Liebregts T, Zschau N, et al. Z-338 improves meal-induced symptoms in Functional Dyspepsia: a double-blind, randomized, placebo controlled crossover study. Gastroenterology 2009;136:A535.
-
(2009)
Gastroenterology
, vol.136
-
-
Adam, B.1
Liebregts, T.2
Zschau, N.3
-
46
-
-
27744573758
-
Influence of experimentally induced anxiety on gastric sensorimotor function in humans
-
DOI 10.1053/j.gastro.2005.08.020, PII S001650850501735X
-
Geeraerts B, Vndenberghe J, Van Oudenhove L, et al. Influence of experimentally induced anxiety on gastric sensorimotor functions in humans. Gastroenterology 2005;129:1437-44. (Pubitemid 41597386)
-
(2005)
Gastroenterology
, vol.129
, Issue.5
, pp. 1437-1444
-
-
Geeraerts, B.1
Vandenberghe, J.2
Van Oudenhove, L.3
Gregory, L.J.4
Aziz, Q.5
Dupont, P.6
Demyttenaere, K.7
Janssens, J.8
Tack, J.9
|